Director boosts stake in Serina Therapeutics (SER) with 20K-share buy

Rhea-AI Filing Summary

Serina Therapeutics director Karen J. Wilson reported open-market purchases of Serina Therapeutics, Inc. common stock. She bought 10,000 shares at a price of $1.77 per share on May 21, 2026 and 10,000 shares at $1.93 per share on May 22, 2026.

After these transactions, Wilson directly owns 20,000 common shares. Footnotes state each reported price is a weighted average for multiple trades, with actual purchase prices ranging from $1.76 to $1.79 and from $1.90 to $1.95 per share.

Insider Trade Summary

Net Buyer: 20,000 shares ($37,000)

Net Buy 2 txns

Insider WILSON KAREN J

Role null

Bought 20,000 shs ($37K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$1.93	$19K
Purchase	Common Stock	10,000	$1.77	$18K

Holdings After Transaction: Common Stock — 20,000 shares (Direct, null)

Footnotes (1)

1. The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.76 per share to a high purchase price of $1.79 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.90 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.

Key Figures

Shares bought May 21, 2026: 10,000 shares Shares bought May 22, 2026: 10,000 shares Total shares purchased: 20,000 shares +3 more

6 metrics

Shares bought May 21, 2026 10,000 shares Open-market purchase at $1.77 per share

Shares bought May 22, 2026 10,000 shares Open-market purchase at $1.93 per share

Total shares purchased 20,000 shares Net open-market buys across both days

Holding after transactions 20,000 shares Director’s direct ownership following May 2026 purchases

Weighted average price range 1 $1.76–$1.79/share Actual trade prices underlying $1.77 weighted average

Weighted average price range 2 $1.90–$1.95/share Actual trade prices underlying $1.93 weighted average

Key Terms

open-market purchase, weighted average purchase price, non-derivative, beneficial ownership

4 terms

open-market purchase financial

"transaction_action: "open-market purchase" for both common stock transactions"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average purchase price financial

"The price reflects the weighted average purchase price of multiple transactions"

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

non-derivative financial

""transaction_type": "non-derivative" for each common stock entry"

beneficial ownership financial

"the reporting person agrees to provide the number of shares sold at each price"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON KAREN J

(Last) (First) (Middle)

601 GENOME WAY

SUITE 2001

(Street)

HUNTSVILLE ALABAMA 35806

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		P		10,000	A	$1.77(1)	10,000	D
Common Stock	05/22/2026		P		10,000	A	$1.93(2)	20,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.76 per share to a high purchase price of $1.79 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.

2. The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.90 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.

Remarks:

	/s/ Karen J. Wilson	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Serina Therapeutics (SER) director Karen J. Wilson do in this Form 4?

Director Karen J. Wilson bought Serina Therapeutics common stock in the open market. She purchased a total of 20,000 shares over two days in May 2026, increasing her direct ownership to 20,000 shares after the reported transactions.

How many Serina Therapeutics (SER) shares did Karen J. Wilson purchase?

Karen J. Wilson purchased 20,000 Serina Therapeutics common shares in total. The Form 4 shows 10,000 shares bought on May 21, 2026 and another 10,000 shares bought on May 22, 2026 in separate open-market transactions.

At what prices did Karen J. Wilson buy Serina Therapeutics (SER) stock?

Wilson bought 10,000 shares at $1.77 per share and 10,000 shares at $1.93 per share. Footnotes explain these are weighted average prices from multiple trades, with actual prices ranging between $1.76–$1.79 and $1.90–$1.95 per share.

What is Karen J. Wilson’s Serina Therapeutics (SER) ownership after these trades?

Following the reported purchases, Karen J. Wilson directly owns 20,000 Serina Therapeutics common shares. The Form 4 specifies this post-transaction holding figure for her direct ownership, reflecting the total after both May 2026 buy transactions.

Were Karen J. Wilson’s Serina Therapeutics (SER) trades single purchases or multiple executions?

Each reported line reflects multiple executions aggregated into a single weighted average price. Footnotes state the May 21 trades ranged from $1.76 to $1.79 per share, and the May 22 trades ranged from $1.90 to $1.95 per share.